First Tracks Biotherapeutics, Inc. (TRAX)

First Tracks Biotherapeutics is a clinical-stage company developing antibody drugs that modulate immune pathways in autoimmune and inflammatory disease. Spun out of AnaptysBio, its pipeline includes programs such as an anti-CD122 antagonist and other immunology candidates aimed at conditions including celiac disease and eosinophilic esophagitis. The company focuses on next-generation antibodies rather than commercial products at this stage.

Market

Nasdaq

Sector

Healthcare

Trend

Uptrend

Last close

40.46 (-4.82% on the day)

MA50

38.17

52-week range

15.32–47.92

Market cap

1.5B USD

Dividend yield

0%

Data as of

2026-09-04

All markets — KeepWinning global stock screener

Other companies on Nasdaq: Tyra Biosciences, Inc. (TYRA), ArriVent BioPharma, Inc. (AVBP), Maze Therapeutics, Inc. (MAZE), Lakeland Financial Corporation (LKFN), InnovAge Holding Corp. (INNV), Schrödinger, Inc. (SDGR)